Forte Biosciences Q1 2024 GAAP EPS $(0.32) Misses $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
Forte Biosciences reported a Q1 2024 GAAP EPS of $(0.32), missing the consensus estimate of $(0.17) by 88.24%.

May 13, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Forte Biosciences reported a significant miss in its Q1 2024 earnings, with a GAAP EPS of $(0.32) versus the expected $(0.17).
Missing earnings estimates significantly, especially by 88.24%, is likely to shake investor confidence and could lead to a short-term decline in stock price. Investors often view earnings misses as a negative indicator of a company's financial health and future prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100